enGene Therapeutics is currently trading below its cash value of $3.97 per share despite risks related to its lead gene therapy asset, detalimogene voraplasmid, which faces FDA approval challenges due to weak 12-month durability data. The company is addressing this by pursuing a surfactant cohort to improve efficacy. Cost-saving measures, including a 50% workforce reduction, have extended the company's cash runway into 2029, supporting operations through key Biologics License Application (BLA) milestones. The analyst maintains a Buy rating, citing a risk-adjusted fair value of $6.65 per share and the downside protection provided by the company's cash position.
KeyBanc initiated coverage on Air Products and Chemicals with a 'Sector Weight' rating, signaling expected performance in line with its sector. Despite the neutral outlook, the company showed strong profitability with a 110 basis point rise in adjust...
RH reported strong Q2 financial results, with earnings per share of $2.70 far exceeding analyst estimates of $0.38 and revenue of $922.20 million beating the $915.09 million forecast. This performance comes despite a recent 25% drop in RH's stock pri...
Tenon Medical's stock surged 116% after repaying $5.16 million in convertible debt, removing dilution risk for shareholders. Wealthfront also rose 15% following strong quarterly earnings that beat expectations. Digital Brands Group and PicoCELA saw s...
Kroger is set to release its earnings report on September 11, 2026, with analysts expecting earnings per share around $1.05-$1.06 and revenues near $34.64-$34.68 billion. Despite growth in digital sales and fresh product categories, the company faces...
On the day GameStop released its earnings report, an insider purchased $1 million worth of company shares. This move suggests strong confidence in the company's future despite market uncertainties. Insider buying often signals positive expectations a...
